Abstract
Abstract Objectives This study determined if melatonin (MLT) can be used with 5-fluorouracil (5-FU), an anticancer drug as adjuvants to reduce A549 lung cancer cell proliferation and sensitise those cells to 5-FU at lower doses while protecting mice from hepatotoxicity. Methods In vitro, MTT assays assessed cell proliferation, and Annexin-V flow cytometry measured A549 cell apoptosis. RT-qPCR measured apoptotic markers tumour suppressor gene P53, KI-67, Bax, Bcl-2, and caspase3; and immunoblotting evaluated cell cycle parameters P21, CDK2, and cyclin E. ELISA biochemical analysis examined liver function, reactive oxygen species (ROS) and antioxidant assays, and inflammatory markers, in vivo. Masson’s trichome, haematoxylin, and eosin stains examined histopathological changes and fibrosis under a microscope. Key findings MLT combined with 5-FU elevated chemo-sensitization by decreasing A549 cell proliferation, lowering the IC50, increasing P21, P53, and Bax, decreasing Bcl-2, Ki-67, CDK2, and cyclin E, and inducing apoptosis and cell cycle arrest at G0/G1. After 5-FU [intraperitoneal (IP)]/MLT (oral) co-administration in vivo, all parameters improved and reversed. Liver enzymes (aspartate aminotransferase and alanine transaminase), bilirubin, albumin, total protein, albumin/globulin ratio, ROS, 4-HNE, H2O2, and pro-inflammatory cytokines; IL-6, IL-1β, and TNFα declined while antioxidant enzymes like SOD, CAT, GSH, and GPx, and IL-10 (anti-inflammatory) increased in combined MLT/5-FU treated groups compared with untreated and 5-FU alone treated groups. Histopathology confirmed these results. Conclusions MLT protected A549 cells from 5-FU-induced hepatotoxicity and enhanced 5-FU’s antitumor effect in vitro. These results support MLT/5-FU’s benefits, suggesting a more effective lung cancer treatment with fewer hepatotoxicity side effects. That could provide a novel therapeutic strategy for lung cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.